关键词:

胰腺癌, SLC7A11, KRAS, SLC7A11抑制剂

Abstract:

Objective To investigate the positive expression of SLC7A11 in KRAS mutant pancreas and the relationship with differentiation，metastasis，staging and prognosis of pancreatic cancer. Methods 54 patients admitted to Sun Yat ⁃ sen Memorial Hospital of Sun Yat ⁃ sen University，from January 1，2019 to December 31， 2021，who were confirmed as pancreatic cancer by surgery and pathology，completed KRAS based detection，and had complete clinical data and follow⁃up conditions were selected. 27 patients showed KRAS mutation in the base detection were set as the experimental group：27 patients without KRAS mutation were set as the control group. The expression of SLC7A11 in surgical and pathological tissues was detected in all cases，and clinical data such as general condition，differentiation degree，lymph node metastasis，tumor size，disease stage，survival period were collected. The positive expression of SLC7A11 was compared between the two groups，andChi square test was used to analyze the relationship between the expression of SLC7A11 and the above factors. Results The positive expres⁃ sion rate of SLC7A11 in KRAS mutant pancreatic cancer was significantly higher than that in the control group （P = 0.002），and the positive expression of SLC7A11 was correlated with the later disease stage（P = 0.000），the worse histological grade（P = 0.003），the more lymph node metastasis（P = 0.038）and the shorter survival period （P = 0.000）. The difference was statistically significant. Conclusions The positive expression rate of SLC7A11 in pancreatic cancer tissues with KRAS mutation is high，and further detection of SLC7A11 expression should be carried out in cases with KRAS mutation. The positive expression of SLC7A11 is associated with worse disease prog⁃ nosis. SLC7A11 inhibitors are likely to be potential targeted drugs for pancreatic cancer.

Key words:

pancreatic cancer, SLC7A11, KRAS, SLC7A11 inhibitors